Understanding how a drug behaves in the body is critical to its success. This whitepaper explores theimportance of accurate pharmacokinetic (PK), pharmacodynamic (PD), and toxicokinetic (TK) data in preclinical trials — and how these insights smooth the path to regulatory approval.
In this whitepaper, you’ll discover:
- How PK, PD, and TK data drive informed drug development decisions
- Challenges with data inconsistencies and how they impact progress
- The power of digitizing and standardizing preclinical reports
- Real-world case study showcasing Excelra’s Preclinical Toxicology Report Digitization (PTRD) solutions
- How accurate PK/TK data accelerates the translation from animal to human studies
This paper offers practical insights into optimizing and interpreting preclinical data, enhancing data integrity, and improving the efficiency of drug development pipelines.
Download the whitepaper to see how accurate, digitized preclinical data helps overcome regulatory roadblocks and shortens time to market.
